The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype

  • Authors:
    • Nicoletta Fortunati
    • Francesca Marano
    • Andrea Bandino
    • Roberto Frairia
    • Maria Graziella Catalano
    • Giuseppe Boccuzzi
  • View Affiliations

  • Published online on: December 19, 2013     https://doi.org/10.3892/ijo.2013.2218
  • Pages: 700-708
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Triple-negative breast cancer (TNBC) is a very aggressive type of tumour and its aggressiveness is linked to E-cadherin downregulation. In estrogen-sensitive breast cancer, high levels of E-cadherin fit with high levels of ERα and MTA3 (a component of the transcription Mi-2/NuRD complex with intrinsic DAC activity). In TNBC the E-cadherin downregulation could be due to epigenetic silencing of the CDH1 gene as well as to the lack of a fully functioning ERα-activated pathway. We report that the pan-histone deacetylase inhibitor LBH589, a potent anti-proliferative agent, induced E-cadherin expression on cell membranes of MDA-MB-231 cells (TNBC), determining a reduction of cell invasion and migration. Even though E-cadherin expression in breast cancer is also regulated by estradiol and the ERα/MTA3/Snail/Slug pathway, LBH589 is able to increase E-cadherin without affecting the estrogen pathway. In fact, no expression of ERα, PR and FoxA1 was observed in MDA-MB-231 cells before and after LBH589 treatment; furthermore, the drug caused an increase in Snail and Slug expression with a concomitant reduction of MTA3 levels. Taking into consideration its anti-proliferative and anti-invasive properties, we suggest the use of LBH589 in aggressive breast cancer refractory to hormonal therapy.
View Figures
View References

Related Articles

Journal Cover

2014-March
Volume 44 Issue 3

Print ISSN: 1019-6439
Online ISSN:1791-2423

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Fortunati N, Marano F, Bandino A, Frairia R, Catalano MG and Boccuzzi G: The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. Int J Oncol 44: 700-708, 2014
APA
Fortunati, N., Marano, F., Bandino, A., Frairia, R., Catalano, M.G., & Boccuzzi, G. (2014). The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype. International Journal of Oncology, 44, 700-708. https://doi.org/10.3892/ijo.2013.2218
MLA
Fortunati, N., Marano, F., Bandino, A., Frairia, R., Catalano, M. G., Boccuzzi, G."The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype". International Journal of Oncology 44.3 (2014): 700-708.
Chicago
Fortunati, N., Marano, F., Bandino, A., Frairia, R., Catalano, M. G., Boccuzzi, G."The pan-histone deacetylase inhibitor LBH589 (panobinostat) alters the invasive breast cancer cell phenotype". International Journal of Oncology 44, no. 3 (2014): 700-708. https://doi.org/10.3892/ijo.2013.2218